Anavex Life Sciences Corp.
AVXL· Nasdaq
Filed Aug 6, 2020 · 10-Q · 37 days after period end · 0001731122-20-000807
| Metric | Q3 2020 | Q3 2019 | Q3 2018 | Q3 2017 |
|---|---|---|---|---|
| Net Income | -$6.49M | -$6.52M | -$2.85M | -$3.61M |
| EPS Diluted | -$0.11 | -$0.13 | -$0.06 | -$0.04 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anavex Life Sciences Corp. · CIK 1314052 · Engraved from SEC EDGAR
ended Jun 30, 2020 · filed Aug 6, 2020 · 37 d after period end